Table 4. Factors related to reactivation of hepatitis B in patients with positive of hepatitis B surface antigen (n = 134) undergoing cytotoxic chemotherapy.

Risk factor	Univariate	p value	Multivariate	p value
	HR (95% CI)		HR (95%CI)
Age (years)	1.01 (0.96–1.06)	0.66
Sex: male	7.90 (0.99–63.15)	0.05	9.86 (1.18–82.16)	0.03
Cancer types	0.87 (0.56–1.33)	0.52
Cirrhosis	0.41 (0.05–3.37)	0.41
Anti-HCV antibody: positive	2.13 (0.23–19.87)	0.51
Liver metastasis	1.29 (0.57–2.89)	0.55
Baseline ALT > 40 IU/mL	2.13 (0.65–7.02)	0.22
Baseline HBV DNA > 2000 IU/mL	2.12 (0.58–7.78)	0.26
HBeAg: positive	0.00	0.99
Antiviral prophylaxis	0.09 (0.01–0.75)	0.03	0.10 (0.01–0.82)	0.03
Chemotherapy agents
Alkylating agents	0.89 (0.23–3.53)	0.87
Anti-metabolites	0.49 (0.14–1.76)	0.28
Antibiotics	0.32 (0.07–1.52)	0.15
Anti-microtubule agents	0.74 (0.15–3.58)	0.71
Topoisomerase inhibitors	4.41 (1.26–15.50)	0.02	3.74 (0.92–15.14)	0.07
Target therapy except for rituximab	1.33 (0.27–6.61)	0.73

ALT, alanine transaminase; HBeAg, hepatitis B e-antigen; HR, hazard ratio.